Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 122 participants.

Also called NCT06645249

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 122 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06645249
  • EU CT 2023-507201-34-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06645249. Randomized; no masking; primary purpose treatment. Start 2024-12-10 (anticipated); primary completion 2026-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation
Acronym
PERIVERSION
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
Amiodarone (Antiarrhythmic drug)
Lead sponsor
Institut Investigacio Sanitaria Pere Virgili (class: other)
Collaborator
Spanish Society of Cardiology (class: other)
Collaborator
Sociedad Espanola de Cardiologia (class: not stated)

Record details

Record id
cardio:ct-nct06645249
Content hash
06262df584b4e31d94c90a037ae0078c4a91a5912a972a51da2bec70b89abd33